{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:55:21Z","timestamp":1760100921341},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.critrevonc.2016.08.009","type":"journal-article","created":{"date-parts":[[2016,9,3]],"date-time":"2016-09-03T06:10:12Z","timestamp":1472883012000},"page":"82-89","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Aromatase inhibitors in premenopause: Great expectations fulfilled?"],"prefix":"10.1016","volume":"107","author":[{"given":"Rosalba","family":"Torrisi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selene","family":"Rota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnese","family":"Losurdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Zuradelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Masci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2016.08.009_bib0005","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1023\/A:1020299707510","article-title":"Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database","volume":"76","author":"Anderson","year":"2002","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0010","unstructured":"Htpps:\/\/www.nccn.org\/professionals\/physician\/_gls\/pdf\/breast."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0015","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1023\/A:1008388823113","article-title":"Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors","volume":"11","author":"Bajetta","year":"2000","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0020","first-page":"585","article-title":"Estrogen levels in premenopausal (prem) patients (pts) with hormone-receptor positive (HR\u2009+\u2009) breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy. Proc ASCO 2014","author":"Bellet","year":"2016","journal-title":"J. Clin. Oncol. Abs."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0025","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S1470-2045(15)00049-2","article-title":"Patient-reported outcomes with adjuvant exemestaneversus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials","volume":"16","author":"Bernhard","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0030","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/annonc\/mdu385","article-title":"ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)","volume":"25","author":"Cardoso","year":"2014","journal-title":"Breast Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0035","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1200\/JCO.2009.24.9565","article-title":"trial of anastrozole plus Goserelin in the treatment of hormone receptor positive metastatic carcinoma of the breast in premenopausal women","volume":"28","author":"Carlson","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0040","first-page":"2261","article-title":"Premenopausal breast cancer patients treated with a gonadotrophin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study","volume":"19","author":"Celio","year":"1999","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0045","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1016\/j.ejca.2010.08.005","article-title":"Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women","volume":"46","author":"Cheung","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0050","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1\u201398","volume":"25","author":"Coates","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"1\u201314","key":"10.1016\/j.critrevonc.2016.08.009_bib0055","article-title":"Tailoring therapies\u2014improving the management of early breast cancer: St gallen international expert consensus on the primary therapy of early breast cancer 2015","volume":"00","author":"Coates","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0060","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1200\/JCO.2007.13.9279","article-title":"Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer","volume":"26","author":"Dixon","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0065","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10549-012-2355-3","article-title":"Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients","volume":"137","author":"Eggemann","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0070","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1023\/A:1013128213451","article-title":"Preoperative treatment of 667 postmenopausal breast cancer patients with letrozole: a random- ized double-blind multicenter study","volume":"12","author":"Eiermann","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0075","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1200\/JCO.2011.40.8666","article-title":"Obesity and risk of recurrence or death following adjuvant endocrine therapy with letrozole or tamoxifen in the BIG 1\u201398 trial","volume":"30","author":"Ewertz","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0080","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1210\/jcem-53-1-192","article-title":"Aromatization of androstenedione to estrone by human adipose tissue in vitro: correlation with adipose tissue mass, age, and endometrial neoplasia","volume":"53","author":"Forney","year":"1981","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0085","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/sj.bjc.6601557","article-title":"Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer","volume":"90","author":"Forward","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0090","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"TEXT and SOFT investigators; international breast cancer study group: adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0095","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1200\/JCO.2002.20.3.751","article-title":"Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study","volume":"20","author":"Geisler","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0100","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0105","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0110","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0115","unstructured":"HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT0041022."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0120","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1210\/jcem-55-4-718","article-title":"Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer","volume":"55","author":"Harris","year":"1982","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0125","first-page":"2013","article-title":"Predictors of recovery of ovarian function during aromatase inhibitor therapy","volume":"1\u20135","author":"Henry","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0130","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0135","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-014-3091-7","article-title":"Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review","volume":"147","author":"Ioannides","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0140","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1016\/j.breast.2013.07.032","article-title":"Optimal systemic therapy for premenopausal women with hormone-receptor positive breast cancer","volume":"22","author":"Jankowitz","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0145","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1158\/1078-0432.CCR-09-1823","article-title":"New strategies in estrogen receptor positive breast cancer","volume":"16","author":"Johnston","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0150","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/jnci\/djg022","article-title":"Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women","volume":"95","author":"Key","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0155","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1200\/JCO.2001.19.2.343","article-title":"Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials","volume":"19","author":"Klijn","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0160","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1210\/jc.2005-2378","article-title":"Comparison of methods to measure low serum estradiol levels in postmenopausal women","volume":"91","author":"Lee","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0165","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1507\/endocrj.EJ12-0434","article-title":"Efficacy of combined therapy of goserelin and letrozole on very young women with advanced breast cancer as first-line endocrine therapy","volume":"60","author":"Liu","year":"2013","journal-title":"Endocr. J."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0170","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.steroids.2014.08.008","article-title":"Estradiol measurements in translational studies of breast cancer","volume":"99","author":"L\u00d8nning","year":"2015","journal-title":"Steroids"},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0175","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1470-2045(11)70373-4","article-title":"Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase II trial","volume":"13","author":"Masuda","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0180","article-title":"Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine and clinical considerations","author":"Maugeri-Sacca\u2018","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0185","first-page":"2370","article-title":"Estrogen suppression in males: metabolic effects","volume":"85","author":"Mauras","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0190","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3892\/or.2013.2312","article-title":"Efficacy of goserelin plus anastrozole in premenopausal womenwith advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial","volume":"29","author":"Nishimura","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0195","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1056\/NEJMoa1404037","article-title":"TEXT and SOFT investigators; international breast cancer study group: adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0200","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1200\/JCO.2009.26.5884","article-title":"Parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy","volume":"28","author":"Park","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0205","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1200\/JCO.2010.33.2585","article-title":"Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial","volume":"29","author":"Pfeiler","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0210","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/annonc\/mdn037","article-title":"Premenopausal endocrine-responsive early breast cancer: who receive chemotherapy","volume":"19","author":"Regan","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0215","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1200\/JCO.2007.13.5319","article-title":"Endocrine effects of adjuvant letrozole+triptorelin compared with tamoxifen+triptorelin in premenopausal patients with early breast cancer","volume":"26","author":"Rossi","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0220","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1677\/erc.0.0060075","article-title":"Use of aromatase inhibitors in breast carcinoma","volume":"6","author":"Santen","year":"1999","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0225","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1210\/jcem-51-3-473","article-title":"Resistance of the ovary to blockade of aromatization with aminoglutethimide","volume":"51","author":"Santen","year":"1980","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0230","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1200\/JCO.2009.27.2021","article-title":"Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial","volume":"28","author":"Sestak","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0235","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0240","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1200\/JCO.2005.05.3694","article-title":"Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines","volume":"24","author":"Smith","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0245","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/bjc.1990.356","article-title":"The clinical and endocrine effects of 4-hidroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer","volume":"62","author":"Stein","year":"1990","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0250","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/1940-6207.CAPR-10-0381","article-title":"Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland","volume":"4","author":"Subbaramaiah","year":"2011","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0255","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10549-008-9912-9","article-title":"Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11\u201393","volume":"113","author":"Th\u00fcrlimann","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0260","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/sj.bjc.6603947","article-title":"Antitumor and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer","volume":"97","author":"Torrisi","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0265","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10549-010-1340-y","article-title":"analogue as preoperative and adjuvant treatment in premenopausal women with ER positive locally advanced breast cancer","volume":"126","author":"Torrisi","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0270","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/tam.5.2.98.102","article-title":"Estradiol in elderly men","volume":"5","author":"Vermeulen","year":"2002","journal-title":"Aging Male"},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0275","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/0277-5379(86)90147-1","article-title":"Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer","volume":"22","author":"Wander","year":"1986","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0280","doi-asserted-by":"publisher","first-page":"e1006","DOI":"10.1097\/MD.0000000000001006","article-title":"Trial of goserelin and exemestane combination therapy in premenopausal women with locally advanced or metastatic breast cancer","volume":"94","author":"Wang","year":"2015","journal-title":"Medicine (Balt.)"},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0285","first-page":"e20","article-title":"Treatment algorithms for hormone receptor-positive advanced breast cancer: applying the results from recent clinical trials into daily practice insights, limitations, and moving forward","author":"Wilson","year":"2013","journal-title":"ASCO Educ. Book"},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0290","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","article-title":"American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004","volume":"23","author":"Winer","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.009_bib0295","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1507\/endocrj.K11E-020","article-title":"Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer","volume":"58","author":"Yao","year":"2011","journal-title":"Endocr. J."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281630186X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281630186X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T05:42:03Z","timestamp":1568353323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084281630186X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":59,"alternative-id":["S104084281630186X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.08.009","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aromatase inhibitors in premenopause: Great expectations fulfilled?","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}